Intra-Cellular Therapies Newsroom

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Analyst UpgradesDec 31, 2024 08:15 ET

Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Stellar 177% Return Over the Last Five Years

Simply Wall StDec 30, 2024 06:23 ET

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?

Yahoo FinanceDec 28, 2024 09:41 ET

S&P 500 Futures Drop In Premarket Trading; Intra-Cellular Therapies, Avantor Lag

Dow JonesDec 17, 2024 07:30 ET

Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More

Seeking AlphaDec 16, 2024 15:45 ET

Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...

BenzingaDec 11, 2024 08:08 ET

Insider Sale: Chairman and CEO of $ITCI (ITCI) Sells 1,534 Shares

Quiver QuantitativeDec 6, 2024 18:16 ET

Intra-Cellular Therapies(ITCI.US) Officer Sells US$8.72 Million in Common Stock

Moomoo NewsDec 6, 2024 18:06 ET

Express News | Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.34 Million in Common Stocks

Moomoo NewsDec 5, 2024 16:30 ET

Express News | Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.37 Million in Common Stocks

Moomoo NewsDec 4, 2024 16:23 ET

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Simply Wall StDec 3, 2024 13:53 ET

Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder

MT NewswiresDec 3, 2024 10:59 ET

Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

ReutersDec 3, 2024 07:30 ET

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Moomoo NewsDec 2, 2024 08:32 ET · Ratings

Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100

Moomoo NewsNov 29, 2024 12:32 ET · Ratings

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

TipRanksNov 27, 2024 20:47 ET · Ratings

Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM

Seeking AlphaNov 26, 2024 14:01 ET

UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87

Moomoo NewsNov 19, 2024 13:31 ET · Ratings

Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79

ReutersNov 19, 2024 10:39 ET

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

GlobeNewswireNov 19, 2024 08:00 ET